Along the same line, the antitumor efficacy of both anti-CTLA4 and anti-PD1 treatments is supported by a specific mixture of bacteria strains that are able to increase the frequency of tumor-infiltrating GrB+IFNγ+CD8+ T cells [68], which in turn suppress tumor growth and prolong progression-free survival in mice. Here, CTLA4 is linked to neoplasm.